A myelofibrosis expert discusses the indications for treatment initiation and transplantation for patients with myelofibrosis.
Videos
An expert on myeloproliferative neoplasms gives an overview of myelofibrosis and assessing patient risk.
Abdulraheem Yacoub, MD, presents the case of a 68-year-old woman with myelofibrosis and offers his initial impressions.
Dr Porter presents recent conference data on a matching-adjusted indirect comparison of amivantamab and mobocertinib for treatment of EGFR exon 20-mutated mNSCLC, and panelists weigh in on factors influencing selection between the two regimens.
Dr Jason Porter presents safety and efficacy data from a Phase 1/2 study on mobocertinib in patients with mNSCLC.
David S. Hong, MD, discusses updated findings from an analysis of 3 trials which ultimately led to the approval of larotrectinib for patients with solid tumors who harbor an NTRK fusion.
Nelson J. Chao, MD, offers closing thoughts on his treatment approach for a 35-year-old woman with chronic GVHD, and looks to the future of GVHD treatment.
A GVHD expert outlines the treatments available for patients with chronic GVHD and steroid-refractory chronic GVHD.
Nelson J. Chao, MD, gives an overview of acute and chronic GVHD, and details the classical presentation and staging process.
An expert on graft-vs-host disease discusses allogeneic stem cell transplantation, and reviews transplant conditioning and GVHD prophylaxis regimens.
Nelson J. Chao, MD, presents a patient profile of a 35-year-old woman diagnosed with chronic graft-vs-host disease, and provides his initial thoughts.
Lajos Pusztai, MD, DPhil, discusses the methods and design of the phase 3 KEYNOTE-522 trial.
Cary Gross, MD, discusses the findings from a retrospective study which revealed there to be an association between Medicaid insurance, rates of biomarker testing, and patient outcomes among patients with advanced non–small cell lung cancer.
Qian Wang, MD, MPH, discusses the changing incidence of small cell lung cancer among patients globally and in the United States.
John Allan, MD, presents the case of a 72-year-old woman with newly diagnosed chronic lymphocytic leukemia and shares his initial impressions.
Jason Luke, MD, discusses how the gated design of the REALITIVITY-047 led to results being delivered in phases for patients with advanced melanoma treated with the combination of relatlimab and nivolumab.
Experts Michael J. Birrer, MD, PhD, and Kimberly Halla, MSN, FNP-C, share insight to a typical patient presentation of MMRp recurrent endometrial carcinoma.
Following their review of clinical trial data behind frontline ALK TKIs in NSCLC, key opinion leaders share practical insight on selection and use of these agents.
Debu Tripathy, MD, discusses the TBCRC049 study which evaluated tucatinib, capecitabine, and trastuzumab in the cerebral spinal fluid of patients with HER2-positive breast cancer and leptomeningeal disease.
Opening its discussion on endometrial carcinoma, a panel of experts led by Robert L. Coleman, MD, reflects on a patient with mismatch repair proficient (MMRp) recurrent disease.
Focusing on the CROWN clinical trial in ALK+ NSCLC, expert panelists consider the role of frontline lorlatinib therapy in this setting.
Ken Kato, MD, PhD, discusses which patient characteristics to look out for when looking to put a patient on the combination of ipilimumab and nivolumab.
Neal Shore, MD, discusses the long-term exposure analysis of darolutamide in the phase 3 ARAMIS Rollover trial for patients with nonmetastatic castration-resistant prostate cancer.
Matthew P. Goetz, MD, discusses the next steps for evaluating treatment with lasofoxifene.
A panel of expert genitourinary oncologists give an overview of renal cell carcinoma and present the case of a 61-year-old man with metastatic clear cell RCC.
In this video, Edwin Choy, MD, discusses the NCCN Clinical Practice Guidelines for treating gastrointestinal stromal tumors.
Andrew Kuykendall, MD, discusses recent approvals seen for patients with myeloproliferative neoplasms.
A brief overview of study design, patient demographics, data from the phase 1 CHRYSALIS trial, which assessed the safety and efficacy of amivantamab in patients with EGFR exon 20-mutated, advanced or metastatic NSCLC.
Continuing the discussion of the presented case of EGFR exon 20-mutant mNSCLC, Dr Velázquez Mañana outlines how the patient experienced disease progression on first-line treatment, after which the panel shares clinical insights and best practices on how they might approach subsequent treatment selection in this scenario.
Pedro C. Barata, MD, MSc, explains how the favorable efficacy and tolerability of lenvatinib and pembrolizumab observed in the CLEAR trial helps provide a standard of care in this patient population.